Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(01): 75-78
DOI: 10.4103/0971-5851.133726
CASE REPORT

Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment

D. Santhosh Kumar
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Hasmukh Jain
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Carcinomatous meningitis or meningeal carcinomatosis is seen in up to 5% of patients of metastatic non-small cell lung cancer. However, isolated carcinomatous meningitis without brain parenchymal metastasis is less common. Patients with carcinomatous meningitis have limited treatment options. However, intrathecal therapy if used optimally along with targeted therapy when indicated result in good palliation with improvement in survival.

Keywords

Carcinomatous meningitis - intrathecal chemotherapy - meningeal carcinomatosis


Publication History

Article published online:
19 July 2021

© 2014. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zachariah B, Zachariah SB, Varghese R, Balducci L. Carcinomatous meningitis: Clinical manifestations and management. Int J Clin Pharmacol Ther 1995;33:7-12.
  • 2 Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: A review. J Neurooncol 2005;75(1):85.
  • 3 Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-19.
  • 4 Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996;53:626-32.
  • 5 Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, et al. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225-9.
  • 6 Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982;49:759-72.
  • 7 Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974;30:138-43.
  • 8 Wolfgang G, Marcus D, Ulrike S. LC: Clinical syndrome in different primaries. J Neurooncol 1998;38:103-10.
  • 9 Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results. Cancer 1998;82:733-9.
  • 10 Mokri B. Low cerebrospinal fluid pressure syndromes. Neurol Clin 2004;22:55-74.
  • 11 Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995;75:2919-31.
  • 12 Mason WP, Yeh SD, DeAngelis LM. 111 Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998;50:438-44.
  • 13 Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012;77:134-9.
  • 14 Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-92.
  • 15 Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: Prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979;6:207-13.
  • 16 Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-5.
  • 17 Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 2003;5:24-8.
  • 18 Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008;10:208-15.
  • 19 Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402.
  • 20 Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2007;59:461-6.
  • 21 Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: Response to high-dose erlotinib. J Clin Oncol 2009;27:e31-2.
  • 22 Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005;64:1625-7.